Clinical Trial Update: Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of coadministering ibrexafungerp with voriconazole in invasive aspergillosis was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Aspergillosis

Drugs mentioned

• Brexafemme (ibrexafungerp)
• VFEND (Voriconazole)

Snippet

Sponsor: Scynexis, Inc. | Conditions: Invasive Pulmonary Aspergillosis | Phase 2 | Status: TERMINATED | Results posted: 2024-08-09